Could Telix shares be a millionaire-maker stock?

MotleyFool

Mar 19

It's been a wild ride for investors in Telix Pharmaceuticals Ltd (ASX: TLX) shares. The biotech star surged to a high of $29.72 nearly a year ago, only to tumble around 56% to $12.29 at the time of ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/2620226319"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2620226319\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2620226319?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-19 21:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620226319","market":"nz","top_or_hot":-1,"title":"Could Telix shares be a millionaire-maker stock?","media":"MotleyFool","content":"<div>\n<p>It's been a wild ride for investors in Telix Pharmaceuticals Ltd (ASX: TLX) shares. The biotech star surged to a high of $29.72 nearly a year ago, only to tumble around 56% to $12.29 at the time of ...</p>\n\n<a href=\"https://www.fool.com.au/2026/03/20/could-telix-shares-be-a-millionaire-maker-stock/\">Source Link</a>\n\n</div>\n","source":"motleyfoolau_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Could Telix shares be a millionaire-maker stock?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCould Telix shares be a millionaire-maker stock?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-19 21:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com.au/2026/03/20/could-telix-shares-be-a-millionaire-maker-stock/><strong>MotleyFool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>It's been a wild ride for investors in Telix Pharmaceuticals Ltd (ASX: TLX) shares. The biotech star surged to a high of $29.72 nearly a year ago, only to tumble around 56% to $12.29 at the time of ...</p>\n\n<a href=\"https://www.fool.com.au/2026/03/20/could-telix-shares-be-a-millionaire-maker-stock/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TLX.AU","symbol_name":"TELIX PHARMACEUTICALS LTD","start_time":0,"source_url":"https://www.fool.com.au/2026/03/20/could-telix-shares-be-a-millionaire-maker-stock/","article_id":"2620226319","we_media_id":null,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/20/could-telix-shares-be-a-millionaire-maker-stock/","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2620226319","pubTimestamp":1773927000,"columns":[],"sourceInfo":{"source_id":"motleyfoolau_stock","name":"MotleyFool"},"weMediaInfo":null,"summary":"It's been a wild ride for investors in Telix Pharmaceuticals Ltd  shares. The biotech star surged to a high of $29.72 nearly a year ago, only to tumble around 56% to $12.29 at the time of writing.That kind of volatility might scare some investors away. But for others, it raises a more intriguing question: Could Telix shares become a long-term winner and turn $50,000 into a $1,000,000?Importantly, Telix has already transitioned into full commercial operations. That sets it apart from many speculative biotech plays still waiting on approvals.As more of its products gain regulatory clearance and clinical adoption increases, revenue has the potential to scale rapidly. In other words, future growth is less about macroeconomic conditions and more about how quickly its therapies are adopted.This week, Telix resubmitted its New Drug Application to the U.S. FDA for TLX101-Px, including new data addressing prior feedback and supporting approval.According to TradingView data, all 16 analysts cove","collect":0,"end_time":0,"defaultTopTitle":"fool.com.au","property":[],"viewcount":null,"language":"en","relate_stocks":{"TLX.AU":"TELIX PHARMACEUTICALS LTD","BK7067":"生物科技"},"translate_title":"Telix股票会成为百万富翁股票吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TLX.AU":1},"content_text":"It's been a wild ride for investors in Telix Pharmaceuticals Ltd (ASX: TLX) shares. The biotech star surged to a high of $29.72 nearly a year ago, only to tumble around 56% to $12.29 at the time of writing. \nThat kind of volatility might scare some investors away. But for others, it raises a more intriguing question: Could Telix shares become a long-term winner and turn $50,000 into a $1,000,000? \nImage source: Getty Images\nA different growth story\nTelix isn't your typical early-stage biotech. The company develops radiopharmaceuticals used in cancer diagnosis and treatment. It operates in a niche combining precision medicine with complex manufacturing and global distribution. \nImportantly, Telix has already transitioned into full commercial operations. That sets it apart from many speculative biotech plays still waiting on approvals. \nAs more of its products gain regulatory clearance and clinical adoption increases, revenue has the potential to scale rapidly. In other words, future growth is less about macroeconomic conditions and more about how quickly its therapies are adopted. \nThat dynamic can create sharp price swings, as seen recently with Telix shares. But it also offers direct exposure to a high-growth corner of healthcare.\nRevenue is booming\nTelix's latest results show just how quickly the business is expanding.\nLast month, the company reported full-year revenue of US$803 million, up 56% year on year and at the lower end of its upgraded guidance range.\nEven more impressive, it expects to generate between US$950 million and US$970 million in revenue this year. That would push it comfortably beyond the $1 billion mark. \nAt the same time, Telix is continuing to invest heavily in future growth, with research and development spending forecast at US$200 million to US$240 million.\nThis combination of strong revenue growth and continued innovation is exactly what long-term investors in Telix shares want to see.\nMajor opportunity, limited competition\nOne of the most exciting developments is Telix's progress in brain cancer.\nThe company recently submitted a European marketing application for TLX101-Px, an imaging agent designed for glioblastoma — one of the most aggressive and difficult-to-treat cancers. \nThis week, Telix resubmitted its New Drug Application to the U.S. FDA for TLX101-Px, including new data addressing prior feedback and supporting approval.\nCrucially, there are currently no widely available commercial alternatives. That gives Telix a rare opportunity to address an urgent medical need with limited direct competition.\nIf successful, this could become a meaningful growth driver for Telix shares in the years ahead.\nWhat do analysts think?\nDespite the share price slump, sentiment remains overwhelmingly positive on Telix shares.\nAccording to TradingView data, all 16 analysts covering ASX biotech stock rate it as a buy or strong buy. Average 12-month price targets suggest Telix shares could climb around 95% to $23.97, with the most bullish forecasts pointing to as high as $31.59. This points to a potential upside of more than 150%. \nThat's a remarkable level of confidence for a stock that has fallen so sharply.\nFoolish Takeaway\nThere's no doubt Telix shares carry risk. Biotech stocks are inherently volatile, and success depends on execution, approvals, and market uptake. \nBut with surging revenues, a growing commercial footprint, and exposure to a high-value medical niche, Telix has the ingredients of a powerful long-term growth story. \nIf it can deliver on its pipeline and scale globally, today's weakness could one day look like an opportunity. The kind that patient investors have million-dollar dreams about.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}